Ready for 2022?
17/09/20 -"Merck confirmed our positive view on the company. As expected, management confirmed the FY 2022 guidance and put some nice colour on 2021. The virtual Investors Day’s main topics gave helpful ..."
Pages
66
Language
English
Published on
17/09/20
You may also be interested by these reports :
20/10/26
The Q3 sales growth surpassed the full-year guidance range, backed by healthy growth in companion and farm animal segments across geographies. The ...
14/10/26
Lonza presented its mid-term outlook at its CMD today in Vacaville (US). The group unveiled ambitious targets, aiming for 10–13% average CER sales ...
14/10/26
Since we last teased Genmab’s (ADD; Denmark) story – a company that specialises in developing antibodies for cancer treatment – in February 2025, the ...
07/10/26
Our estimates are already at the higher end, with our target price significantly benefitting from increased NAV and DCF estimates, as well as a ...